Abstract 241P
Background
Human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV-associated OPSCC) is well known to have a relatively indolent behavior, and it should be staged separately. P16 is a useful surrogate marker for HPV status in OP region. However, the low prevalence of HPV infection in Taiwan (lower than 30%) may cause increased possibility of false positive for p16 staining. This study is aimed to determine the concordance of p16 IHC stain and HPV RNA ISH in Taiwan population.
Methods
There were 141 oropharyngeal cancer patients are retrieved from the archives of VGHTC from 2016 to 2020. HE stain was done and reviewed by 2 pathologist and p16 IHC stain was performed for all cases. Forty-nine (34.8%) of all cases were p16(+) oropharyngeal cancer. HPV-ISH was done for p16(+) oropharyngeal cancer patients.
Results
HPV-ISH found 44 (89.7%) of 49 cases were HPV-ISH (+). On univariate analysis, p16 (+) oropharyngeal cancer patients had better 3-year overall survival (90.4 % vs. 73.4 %, p=0.02) and 3-year disease-free survival (95.4% vs. 65.3%, p=0.0005) than p16(-) oropharyngeal cancer patients. HPV-ISH (+) oropharyngeal cancer patients also had better 3-year overall survival (92.0 % vs. 73.5 %, p=0.02) and 3-year disease-free survival (94.9% vs. 67.4%, p=0.002) than HPV-ISH(-) oropharyngeal cancer patients. We also found p16(+)HPVISH(+) oropharngeal cancer patients had better 3-year disease-free survival than p16(-)HPVISH(-) oropharngeal cancer patients (94.9% vs. 65.3%, p=0.002).
Conclusions
By far, p16 is still a useful surrogate marker for OPSCC in Taiwan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
186P - Degradation of BRCA2 expression by hyperthermia sensitizes HRD-negative (BRCA2 wild-type) ovarian cancer cells to niraparib
Presenter: Junyang Li
Session: Poster viewing 03
187P - BUB1 (2530C>T) polymorphism and expression affects chemotherapy response and predicts poor prognosis in advanced epithelial ovarian cancer
Presenter: Sinjini Sarkar
Session: Poster viewing 03
188P - Spatial transcriptomic analysis of tumor tissue in ovarian cancer patients treated with neoadjuvant chemotherapy
Presenter: Irina Larionova
Session: Poster viewing 03
189P - LncRNA NKILA as a negative regulator of NFkB in ascites in ovarian cancer
Presenter: Dinara Dolgova
Session: Poster viewing 03
190P - Real-world applications of poly (ADP-ribose) polymerase inhibitors for ovarian cancer: A single-center study in China
Presenter: dengfeng wang
Session: Poster viewing 03
191P - Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
Presenter: N Thejeswar
Session: Poster viewing 03
192P - Human epididymis protein 4 as a predictor of response to neoadjuvant chemotherapy in epithelial ovarian cancer
Presenter: Sarada Planjery
Session: Poster viewing 03
193P - Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice: Experience of re-challenge mode of olaparib usage
Presenter: Alexander Sultanbaev
Session: Poster viewing 03
194P - A study of the treatment response of concomitant external beam radiotherapy (EBRT) and intracavitary brachytherapy in the management of locally advanced carcinoma of uterine cervix
Presenter: Asish Chowdhury
Session: Poster viewing 03
195P - Awareness of human papillomavirus (HPV) infection, cervical cancer (CC), and vaccine among females in Sultanate of Oman
Presenter: Abdulrahman Al-Mirza
Session: Poster viewing 03